

REMARKS

Upon entry of the foregoing amendments, claims 1 to 6, 21, 22, 24 to 27, 30 to 36, and 38 to 52, will be pending in this patent application. Claims 30 to 35, 38, 39, 44, and 45 have been amended without prejudice. Claims 28, 29 and 37 have been canceled without prejudice. Claims 46 to 52 are new. Support for claims 46 to 52 is found throughout Applicants' specification such as, for example, in original claims 36 to 43.

The Action includes rejections under 35 U.S.C. § 112, first paragraph. In view of the foregoing amendments and the following remarks, reconsideration and withdrawal of the rejections are respectfully requested.

Discussion of the Rejection Under 35 U.S.C. § 112, First Paragraph

Claims 30 to 45 have been rejected under 35 U.S.C. § 112, first paragraph, as allegedly containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to make and/or use the invention. Although Applicants disagree respectfully with the rejection, Applicants have amended the claims to render the rejection moot. In this regard, Examiner Saeed confirmed that claim 37 was allowable during a telephone conference with Applicants' representative, the undersigned.¹ Thus, for the sole purpose of advancing prosecution of this patent application, the method claims were amended to mirror the scope of claim 37. Applicants reserve the right to present the subject matter deleted from the above claims in a later-filed continuation application. Accordingly, reconsideration and withdrawal of the rejection is requested respectfully.

¹ Applicants' representative suspected that claim 37 was allowable because the Action, at page 3, did not allege that the scope of claim 37 was not enabled.

Conclusion

Applicants believe that the foregoing constitutes a complete and full response to the Office Action of record. Applicants respectfully submit that this application is now in condition for allowance. Accordingly, an indication of allowability and an early Notice of Allowance are respectfully requested.

The Commissioner is hereby authorized to charge the fee required and any additional fees that may be needed to Deposit Account No. **18-1982** in the name of Aventis Pharmaceuticals Inc.

Respectfully submitted,

Dated: June 8, 2006

/Joseph D. Rossi/
Joseph D. Rossi
Registration No. 47,038
Attorney for Applicants

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800
Telephone: 908-231-3410
Telefax: 908-231-2626
Docket No. DEAV2001/0004 US NP